The IMpassion130 trial in Metastatic Triple-Negative Breast Cancer
Rita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.
Rita Nanda, MD, associate professor of medicine and director of the Breast Oncology Program at The University of Chicago, discusses the IMpassion130 trial in patients with metastatic triple-negative breast cancer (TNBC) who express PD-L1.
The IMpassion130 trial has been practice-changing for Nanda and many other providers, creating a new standard of care for women with metastatic TNBC whose cancer expresses the PD-L1 protein. Pembrolizumab is not yet approved in the neoadjuvant setting, but Nanda is hopeful it will come.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
